九洲药业：产品“甲苯磺酸艾多沙班”取得注册证

Group 1 - The core point of the article is that Jiuzhou Pharmaceutical has received approval for its drug, Tofisopam, from the National Medical Products Administration, which is expected to enhance its product portfolio and revenue potential [1] - Jiuzhou Pharmaceutical's revenue composition for 2024 indicates that 98.56% of its income will come from the production and sales of chemical raw materials and intermediates, while other businesses contribute only 1.44% [1] - As of the report, Jiuzhou Pharmaceutical has a market capitalization of 19.1 billion yuan [1]